Colorectal Cancer
Modified capecitabine regimen effective in colorectal cancer
Published in Blood Weekly, May 20th, 2004
A "modified Japanese capecitabine regimen as first-line treatment for advanced/ metastatic colorectal cancer" was evaluated in a phase II study. "Sixty patients received oral capecitabine 828 mg/m2 twice daily for 3 weeks every 4 weeks," wrote researchers in Japan.
"In the 56 efficacy-evaluable patients, the overall response rate was 26.8% (95% Cl 15.8-40.3%) and 21 patients (37.5%) had stable disease. The median duration of response and overall survival times were 7.4 months (range 4.3-13.8) and 17.6 months (95% CI 14.1-20.5), respectively," J. Sakamoto and colleagues...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2004-05-20)
More Articles from Blood Weekly
- Adverse Drug Effects
Long-term studies show transduced stem cells do not cause leukemia - Cancer Risk Factor
Celiac disease not a risk factor for lymphoma - Drug Delivery
Heparin-coated nanoparticles show promise as oxygen carriers - HIV/AIDS
Company presents data on its therapeutic vaccine approach for HIV infection - Liver Damage
Preclinical data presented on histamine's ability to prevent liver damage - Acute Myeloid Leukemia
Adult patients with t(8;21) AML had similar outcomes as non-t(8;21) patients - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
